Led · Series C · Feb 2026

Founded in late 2019, Loyal is focused on creating the first FDA-approved therapeutics that slow or reverse the metabolic drivers of aging in dogs. Its lead candidate, LOY-002, is a prescription daily pill intended to prolong the healthy years of senior dogs and has already satisfied the Reasonable Expectation of Effectiveness and Target Animal Safety portions of its Expanded Conditional Approval application. Loyal has three drugs in development and recently completed enrollment of 1,300 dogs across 70 veterinary clinics for its pivotal STAY trial, the largest clinical study in veterinary medicine. With regulatory progress well underway, the company plans to submit the final section of the LOY-002 dossier to the FDA later this year. The new capital will fund team expansion, distribution build-out, and market-launch preparations. Loyal has raised more than $250 million to date, underscoring strong investor confidence in the commercial potential of canine longevity therapeutics.

Led · Series A · Feb 2026

Aerska is developing delivery technologies intended to enable systemic delivery of RNA medicines to the brain to treat serious neurological diseases. The company is focused on improving selectivity of RNAi payload delivery and on approaches that could target multiple disease pathways simultaneously. Aerska announced an additional $10M investment from GHIC as part of its Series A, indicating ongoing Series A financing activity. The company positions the GHIC investment as a partnership to advance its platform toward clinical or translational goals. No public operating metrics or founding date were disclosed in the announcement.

Participated · Equity · Nov 2025

Skeletalis is developing next-generation therapeutics aimed at musculoskeletal disorders, with an initial focus on osteoporosis. Its lead small-molecule candidate employs a proprietary bone-targeting technology that delivers disease-modulating therapy directly to skeletal tissue, minimizing systemic exposure. By re-engineering drug engagement with bone targets, the company seeks to improve tolerability, extend therapeutic durability, and ultimately prevent fractures while preserving bone mineral density. The approach is designed to avoid the safety liabilities associated with current osteoporosis drugs. Skeletalis is led by founder and CEO Ben Swanson, DDS, PhD, working alongside Dr. Colin Greineder. The recently secured financing will fund advancement of the osteoporosis candidate through pre-clinical and early clinical development. No operating metrics such as revenue or user count have been disclosed.

Participated · Seed · Jan 2025

General Proximity has built the OmniTAC platform, a mechanism-agnostic proximity discovery engine that scans the "effectome"—effector proteins that can modulate disease-relevant targets. The company is advancing multiple preclinical programs across oncology, cardiometabolic disease, neurodegeneration, and longevity. Its track record includes over $20 million raised to date, five "Golden Ticket" awards from major pharma companies, and non-dilutive grants from ARPA-H and the NIH's National Cancer Institute. General Proximity also announced a strategic multi-target collaboration with Daiichi Sankyo. The company is headquartered in San Francisco and is positioning its platform to unlock targets previously considered beyond the reach of medicine.